Deletion of chromosome 9p21 noncoding cardiovascular risk interval in mice alters Smad2 signaling and promotes vascular aneurysm

Circulation: Cardiovascular Genetics

Volumn 7, Issue 6, 2014, Pages 799-805

  Loinard, Céline ^a   Basatemur, Gemma ^a   Masters, Leanne ^a   Baker, Lauren ^a   Harrison, James ^a   Figg, Nichola ^a   Vilar, José ^b   Sage, Andrew P ^a   Mallat, Ziad ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSERM   (France)

Author keywords

Aneurysm; Animal; Genetics; Models; Myocytes; Smooth muscle

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2D; FLAVONOID; FLAVOPIRIDOL; MACROPHAGE ELASTASE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANEURYSM; ANEURYSM RUPTURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 9P; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE PREDISPOSITION; GENE; GENE DELETION; MOUSE; NONHUMAN; P15INKB GENE; P19ARF GENE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VASCULAR ANEURYSM; VASCULAR SMOOTH MUSCLE; ANIMAL; C57BL MOUSE; CELL CULTURE; CHROMOSOME; CYTOLOGY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; PHOSPHORYLATION; RISK FACTOR;

ANIMALIA; MUS;

ANEURYSM; ANIMALS; CELLS, CULTURED; CHROMOSOMES; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P19; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FLAVONOIDS; GENE EXPRESSION; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 12; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; RISK FACTORS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84925863848     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000696     Document Type: Article

References (45)

1. Nordon IM, Hinchliffe RJ, Loftus IM, Thompson MM. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat Rev Cardiol. 2011;8:92-102
2. Michel JB, Martin-Ventura JL, Egido J, Sakalihasan N, Treska V, Lindholt J, Allaire E, et al; FAD EU Consortium. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res. 2011;90:18-27
3. Helgadottir A, Thorleifsson G, Magnusson KP, Grétarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008;40:217-224
4. Golledge J, Kuivaniemi H. Genetics of abdominal aortic aneurysm. Curr Opin Cardiol. 2013;28:290-296
5. Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, Simon M, et al. Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet. 2010;42:420-425
6. Nakaoka H, Takahashi T, Akiyama K, Cui T, Tajima A, Krischek B, Kasuya H, et al. Differential effects of chromosome 9p21 variation on subphenotypes of intracranial aneurysm: site distribution. Stroke. 2010;41:1593-1598
7. Hashikata H, Liu W, Inoue K, Mineharu Y, Yamada S, Nanayakkara S, Matsuura N, et al. Confirmation of an association of single-nucleotide polymorphism rs1333040 on 9p21 with familial and sporadic intracranial aneurysms in Japanese patients. Stroke. 2010;41:1138-1144
8. Visel A, Zhu Y, May D, Afzal V, Gong E, Attanasio C, Blow MJ, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature. 2010;464:409-412
9. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612
10. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, et al. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432
11. Klink A, Heynens J, Herranz B, Lobatto ME, Arias T, Sanders HM, Strijkers GJ, et al. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. J Am Coll Cardiol. 2011;58:2522-2530
12. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483-488
13. Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 1996;9:1143-1168
14. Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest. 1998;102:1674-1681
15. Forrest ST, Taylor AM, Sarembock IJ, Perlegas D, McNamara CA. Phosphorylation regulates Id3 function in vascular smooth muscle cells. Circ Res. 2004;95:557-559
16. Taleb S, Herbin O, Ait-Oufella H, Verreth W, Gourdy P, Barateau V, Merval R, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:2691-2698
17. Li W, Li Q, Jiao Y, Qin L, Ali R, Zhou J, Ferruzzi J, et al. Tgfbr2 disruption in postnatal smooth muscle impairs aortic wall homeostasis. J Clin Invest. 2014;124:755-767
18. Adam PJ, Regan CP, Hautmann MB, Owens GK. Positive-and negativeacting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo. J Biol Chem. 2000;275:37798-37806
19. Hirschi KK, Lai L, Belaguli NS, Dean DA, Schwartz RJ, Zimmer WE. Transforming growth factor-beta induction of smooth muscle cell phenotpye requires transcriptional and post-transcriptional control of serum response factor. J Biol Chem. 2002;277:6287-6295
20. Xie WB, Li Z, Miano JM, Long X, Chen SY. Smad3-mediated myocardin silencing: a novel mechanism governing the initiation of smooth muscle differentiation. J Biol Chem. 2011;286:15050-15057
21. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F. Cyclindependent kinases regulate the antiproliferative function of Smads. Nature. 2004;430:226-231
22. Cohen-Solal KA, Merrigan KT, Chan JL, Goydos JS, Chen W, Foran DJ, Liu F, et al. Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor,-mediated growth inhibition. Pigment Cell Melanoma Res. 2011;24:512-524
23. Motterle A, Pu X, Wood H, Xiao Q, Gor S, Ng FL, Chan K, et al. Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum Mol Genet. 2012;21:4021-4029
24. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, et al. 9p21 DNA variants associated with coronary artery disease impair interferon, signalling response. Nature. 2011;470:264-268
25. Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, Clarke R, et al; PROCARDIS Consortium. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet. 2008;17:806-814
26. Jarinova O, Stewart AF, Roberts R, Wells G, Lau P, Naing T, Buerki C, et al. Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol. 2009;29:1671-1677
27. Zhang W, Chen Y, Liu P, Chen J, Song L, Tang Y, Wang Y, et al. Variants on chromosome 9p21.3 correlated with ANRIL expression contribute to stroke risk and recurrence in a large prospective stroke population. Stroke. 2012;43:14-21
28. Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL, Ibrahim JG, et al. INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One. 2009;4:e5027
29. Cunnington MS, Santibanez Koref M, Mayosi BM, Burn J, Keavney B. Chromosome 9p21 SNPs associated with multiple disease phenotypes correlate with ANRIL Expression. PLoS Genet. 2010;6:e1000899
30. Holdt LM, Teupser D. Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc Biol. 2012;32:196-206
31. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010;38:662-674
32. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30:1956-1962
33. Congrains A, Kamide K, Oguro R, Yasuda O, Miyata K, Yamamoto E, Kawai T, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis. 2012;220:449-455
34. Topouzis S, Majesky MW. Smooth muscle lineage diversity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factorbeta. Dev Biol. 1996;178:430-445
35. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658
36. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462
37. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79
38. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, Merval R, Fradelizi D, et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res. 2001;89:930-934
39. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 2003;112:1342-1350
40. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24:399-404
41. Holm TM, Habashi JP, Doyle JJ, Bedja D, Chen Y, van Erp C, Lindsay ME, et al. Noncanonical TGF signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science. 2011;332:358-361
42. van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43:121-126
43. Lindsay ME, Dietz HC. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature. 2011;473:308-316
44. Morris DG, Huang X, Kaminski N, Wang Y, Shapiro SD, Dolganov G, Glick A, et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature. 2003;422:169-173
45. Leeper NJ, Raiesdana A, Kojima Y, Kundu RK, Cheng H, Maegdefessel L, Toh R, et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol. 2013;33:e1-e10.